Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul;1(1):35-41.
doi: 10.1111/j.1753-5174.2008.00006.x.

Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats

Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats

Hani Al-Salami et al. Arch Drug Inf. 2008 Jul.

Abstract

AIM: To investigate the influence of probiotic pre-treatment on the permeation of the antidiabetic drug gliclazide in healthy and diabetic rats. METHODS: Wistar rats (age 2-3 months, weight 350 +/- 50 g) were randomly allocated into one of 4 groups (N = 16 each group): healthy control, healthy probiotic, diabetic control, and diabetic probiotic. Probiotics (75 mg/kg, equal quantities of Lactobacillus acidophilus, Bifidobacterium lactis, and Lactobacillus rhamnosus) were administered twice a day for three days to the appropriate groups after diabetes had been induced with alloxan i.v. 30 mg/kg. Rats were sacrificed, ileal tissues mounted in Ussing chambers and gliclazide (200 microg/mL) was administered for the measurement of the mucosal to serosal absorption Jss((MtoS)) and serosal to mucosal secretion Jss((StoM)) of gliclazide. RESULTS: Treatment of healthy rats with probiotics reduced Jss((MtoS)) of gliclazide from 1.2 +/- 0.3 to 0.3 +/- 0.1 microg/min/cm(2) (P < 0.01) and increased Jss((StoM))from 0.6 +/- 0.1 to 1.4 +/- 0.3 (P < 0.01) resulting in net secretion while, in diabetic tissues, treatment with probiotics increased both Jss((MtoS)) and Jss((StoM))fluxes of gliclazide to the comparable levels of healthy tissues resulting in net absorption. DISCUSSION: In healthy rats, the reduction in Jss((MtoS)) after probiotics administration could be explained by the production of bacterial metabolites that upregulate the mucosal efflux drug transporters Mrp2 that control gliclazide transport. In diabetic rats, the restored fluxes of gliclazide after probiotic treatment, suggests the normalization of the functionality of the drug transporters resulting in a net absorption. CONCLUSION: Probiotics may alter gliclazide transport across rat ileal tissue studied ex vivo.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Gliclazide permeation through the ileal enterocytes through the action of the efflux transporters Mrp2 and Mrp3. G: gliclazide, G-: the negative ion of gliclazide molecule and H+: the proton produced from gliclazide ionization. Mrp: multi-resistance associated protein transporter. 5%: the percentage of the unionized gliclazide molecule inside the enterocytes (ileal mucosa). 95%: the percentage of the ionized gliclazide molecules inside the enterocytes.

Similar articles

Cited by

References

    1. FAO/WHO. Guidelines for the Evaluation of Probiotics in Food. 2002. in Joint FAO/WHO Working Group Report on Drafting Guidelines for the evaluation of Probiotics in Food.
    1. Bezkorovainy A. Probiotics: Determinants of survival and growth in the gut. Am J Clin Nutr. 2001;73(suppl 2):399S–405S. - PubMed
    1. Karimi O, Pena AS. Probiotics: Isolated bacteria strain or mixtures of different strains? Two different approaches in the use of probiotics as therapeutics. Drugs Today. 2003;39:565–97. - PubMed
    1. Pena JA, Versalovic J. Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol. 2003;5:277–85. - PubMed
    1. Kruis W. Review article: Antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(suppl 4):75–8. - PubMed

LinkOut - more resources